What is included in after treatment monitoring of breast masses?

Updated: Jul 27, 2020
  • Author: Andrew C Miller, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD  more...
  • Print
Answer

For breast cancer screening guidelines, see the Guidelines section.

Future studies are needed to determine the efficacy and effectiveness of breast cancer screening with mammography in women aged 40-49 years. Some research shows a modest decrease in breast cancer mortality when women in this age group are screened; however, further research is needed to compare risks of overdiagnosis (one study suggests 1 in 424 women screened would be overdiagnosed) versus potential benefits of screening. [30, 77]

Similar rates of cancer detection have been found between short-term interval follow-up (SIFU) and return to annual screening (RTAS) after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. [78] Additionally, positive predictive values have been reported not to change in patients receiving 6 and 12-month re-biopsy follow-up. [79] These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!